Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 21, 2005 Brian Gorman	Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note.
BusinessWeek July 1, 2010 Doherty & Waters	Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand
The Motley Fool December 18, 2009 Brian Orelli	Buy a Company, Get the Plant for Free Earlier this year, Merck company bought a pipeline of follow-on biologics (and a manufacturing plant to make them in) from Insmed. Now it's back for more with an acquisition of Avecia Biologics.
Chemistry World October 29, 2014 Phillip Broadwith	CHF3bn redevelopment for Roche's Basel site Swiss pharma major Roche plans to spend CHF3 billion ( 2 billion pounds) over the next 10 years on redeveloping its headquarters in Basel.
BusinessWeek November 25, 2009 Arlene Weintraub	Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance.
The Motley Fool June 25, 2007 Brian Orelli	Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note.
The Motley Fool July 21, 2008 Brian Lawler	Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own.
Chemistry World June 12, 2012 Nina Notman	Three pronged approach puts brakes on US breast cancer The US Food and Drug Administration (FDA) has approved the use of anti-HER2 therapy Perjeta (pertuzumab) to treat patients with previously untreated HER2-positive metastatic breast cancer.
The Motley Fool August 31, 2010 Rich Duprey	Why Did My Stock Just Die? These stocks just rolled over. Can they come back?
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
The Motley Fool February 13, 2009 Brian Orelli	The Easy Way to Develop Drugs Merck buys a pipeline of follow-on biologics and a building to produce them.
The Motley Fool September 9, 2011 Frank Vinluan	GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche.
The Motley Fool December 15, 2004 Brian Gorman	Korea's Biotech Bet Korea's new facility could stimulate biotech research in Asia and lower costs for biotech companies.
Chemistry World June 26, 2012 Patrick Walter	Roche cuts 1000 jobs with US R&D site closure The shuttering of its only East Coast R&D site is part of a streamlining drive which will see research activities from the Nutley site moved to Germany and Switzerland.
The Motley Fool June 21, 2011 Brian Orelli	Data Look Good, Approval Unknown Accelerated approvals are like that. The data should give Curis' investors added confidence that vismodegib works, but whether it can get approved with this limited data remains to be seen.
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
The Motley Fool August 22, 2011 Brian Orelli	Speedy in Seattle Seattle Genetics gets an early approval of Adcentris.
The Motley Fool October 17, 2006 Brian Lawler	Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at.
Chemistry World September 7, 2015	Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool March 31, 2011 Brian Orelli	Better Buy? Seattle Genetics or ImmunoGen Battle of the heat-seeking cellular missiles.
The Motley Fool May 18, 2011 Brian Orelli	If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship.
Chemistry World January 28, 2015 Rebecca Trager	Roche chases bolt-on acquisitions as it pushes into genomics A recent spending spree by Roche is intended to take advantage of emerging molecular information and genomic analysis, as the company anticipates that the field will play an increasingly important role for future medicines and diagnostics.
The Motley Fool January 6, 2012 Brian Orelli	Don't Read Too Much Into This Partnership While the partnership is not a sign that Roche will buy Aeterna Zentaris, there's no doubt that the development of AEZS-108 makes the biotech a more attractive takeout candidate.
The Motley Fool April 17, 2006 Brian Gorman	Novartis Presses on Biogenerics The company wins a court case that could accelerate U.S. regulations for biogenerics. Recent developments suggest Novartis' strategy may be close to paying off. Investors, take note.
Chemistry World August 29, 2014 Sarah Houlton	Roche to buy InterMune for respiratory boost Roche is to acquire InterMune in a deal worth $8.3 billion.
The Motley Fool August 27, 2010 Brian Orelli	Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen.
The Motley Fool January 28, 2011 Luke Timmerman	Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up.
The Motley Fool April 5, 2004 Charly Travers	A Biotech's Transition to Drugs A deal with Roche gives ArQule's drug program a leg up. ArQule has spent the last year transitioning from a services company into a drug developer. Last week's deal with Roche could signify that the transition is complete.
The Motley Fool January 31, 2008 Brian Lawler	Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention.
The Motley Fool July 20, 2005 Stephen D. Simpson	Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead.
The Motley Fool July 16, 2007 Brian Orelli	Ventana Says No, We Can't Talk In many ways, Ventana is actually a perfect match for Roche. But for now, this hostile takeover bid is stalled. Investors, take note.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
IndustryWeek July 22, 2009 Jonathan Katz	America's View of Manufacturing: By the Numbers Deloitte's 'Public Viewpoint on Manufacturing' study highlights manufacturing's importance in the U.S. economy.
Pharmaceutical Executive November 1, 2005 Sarah Houlton	Global Report: Drug Evaluation in the UK The availability of new medicines has been thrown into the limelight once more, with UK's National Institute for Health and Clinical Excellence being called upon to make dramatic improvements to the speed at which it carries out evaluations.
The Motley Fool September 25, 2007 Billy Fisher	Bristol-Myers Buys In to Biologics Looking to advance its biologics strategy, Bristol-Myers Squibb announces it will acquire Adnexus Therapeutics, a privately held developer of biologics.
Fast Company January 2002 George Anders	Roche's New Scientific Method How does a giant pharmaceutical company reckon with genomics technology? By making a fresh start in how it recruits its scientists, manages projects, and uses computers. Here's how the Roche Group is reinventing how it invents...
Pharmaceutical Executive April 1, 2006 Ron Feemster	Thought Leader: Q&A with Joel A. Tune Pharma still enlists contract manufacturers as safety valves, but today's drug developers have also begun to outsource the production of increasingly complicated compounds while they are still in clinical trials.
Fast Company February 2009 Elizabeth Svoboda	Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits.
Chemistry World January 27, 2012 Sarah Houlton	Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach.
IndustryWeek June 1, 2006 Patricia Panchak	Editor's Page -- U.S. Manufacturing's Global Future Here's what we can learn from big energy's strong showing.
The Motley Fool October 26, 2007 Brian Orelli	Investing in Follow-On Biologics Investors, while approvals of follow-on biologics in the U.S. are probably still years away, now is the time to do your research. Those that are leading the race overseas are likely to be first in line when the FDA opens its door to applications.
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.
The Motley Fool October 18, 2011 Evan Niu	Halozyme Therapeutics Shares Surged: What You Need to Know Shares of Halozyme Therapeutics are surging by as much as 22.5% today on news that, together with partner Roche Holding, the company has reported positive results from a trial study regarding one of its drugs.
BusinessWeek October 1, 2007 Conrad Wilson	A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution.
The Motley Fool June 22, 2005 Brian Gorman	Biotech's Global Agenda Bristol-Myers' recent outsourcing deal illustrates the global spread of biotech investments.
The Motley Fool August 22, 2007 Brian Orelli	Yes? No? Maybe So? Roche is still after Ventana. While longtime investors are happy that Roche pointed out Ventana's undervaluation to the rest of the world, current investors think Roche's offer is still too low.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
The Motley Fool August 14, 2008 Brian Lawler	Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid.